| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT01058707 | Advanced Solid Malignancies | Drug: MLN0128 | Millennium Pharmaceuticals, Inc.|Takeda | Phase 1 | 2010-01-01 | 2017-01-03 |
| NCT02244463 | Anaplastic Thyroid Cancer|Thyroid Cancer | Drug: MLN0128 | Dana-Farber Cancer Institute|Millennium Pharmaceuticals, Inc. | Phase 2 | 2015-07-01 | 2016-09-09 |
| NCT02514824 | Merkel Cell Carcinoma | Drug: MLN0128 | Dana-Farber Cancer Institute|Millennium Pharmaceuticals, Inc. | Phase 1|Phase 2 | 2015-10-01 | 2016-12-29 |
| NCT02503722 | Recurrent Non-Small Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer | Other: Laboratory Biomarker Analysis|Drug: Osimertinib|Other: Pharmacological Study|Drug: Sapanisertib | National Cancer Institute (NCI) | Phase 1 | 2016-10-01 | 2017-03-14 |
| NCT01351350 | Advanced Solid Malignancies|Hematologic Malignancies | Drug: MLN0128 + paclitaxel|Drug: MLN0128 + paclitaxel + trastuzumab | Millennium Pharmaceuticals, Inc. | Phase 1 | 2011-03-01 | 2015-04-07 |
| NCT02719691 | Metastatic Breast Cancer|Solid Tumors | Drug: Alisertib|Drug: MLN0128 | University of Colorado, Denver | Phase 1 | 2016-05-01 | 2016-11-07 |
| NCT02197572 | Advanced Solid Tumors | Drug: MLN0128 | Millennium Pharmaceuticals, Inc.|Takeda | Phase 1 | 2014-09-01 | 2017-01-12 |
| NCT01118689 | Relapsed Multiple Myeloma|Refractory Multiple Myeloma|Waldenstrom Macroglobulinemia | Drug: MLN0128 | Millennium Pharmaceuticals, Inc. | Phase 1 | 2010-11-01 | 2013-07-31 |
| NCT02575339 | Hepatocellular Carcinoma|Liver Cancer|HCC | Drug: MLN0128|Drug: MLN0128 (RP2D)|Drug: Sorafenib | Bert O'Neil, MD|Hoosier Cancer Research Network|Millennium Pharmaceuticals, Inc.|Big Ten Cancer Research Consortium | Phase 1|Phase 2 | 2016-07-01 | 2017-01-19 |
| NCT02484430 | Recurrent Adult Acute Lymphoblastic Leukemia | Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Sapanisertib | National Cancer Institute (NCI) | Phase 2 | 2016-10-01 | 2017-03-23 |
| NCT02091531 | Metastatic Castration-Resistant Prostate Cancer | Drug: MLN0128 | Memorial Sloan Kettering Cancer Center|Millennium Pharmaceuticals, Inc. | Phase 2 | 2014-03-01 | 2016-11-21 |
| NCT02412722 | Non-Hematologic Malignancy | Drug: Milled MLN0128 API|Drug: Unmilled MLN0128 API|Drug: Paclitaxel | Millennium Pharmaceuticals, Inc.|Takeda | Phase 1 | 2015-03-01 | 2017-01-11 |
| NCT01899053 | Advanced Nonhematologic Malignancies | Drug: MLN0128|Drug: MLN1117 | Millennium Pharmaceuticals, Inc.|Takeda | Phase 1 | 2013-07-01 | 2016-11-08 |
| NCT02142803 | Adult Glioblastoma|Endometrial Clear Cell Adenocarcinoma|Endometrial Serous Adenocarcinoma|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Serous Cystadenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Recurrent Uterine Corpus Carcinoma|Solid Neoplasm|Stage IIIA Fallopian Tube Cancer|Stage IIIA Ovarian Cancer|Stage IIIA Primary Peritoneal Cancer|Stage IIIB Fallopian Tube Cancer|Stage IIIB Ovarian Cancer|Stage IIIB Primary Peritoneal Cancer|Stage IIIC Fallopian Tube Cancer|Stage IIIC Ovarian Cancer|Stage IIIC Primary Peritoneal Cancer|Stage IV Fallopian Tube Cancer|Stage IV Ovarian Cancer|Stage IV Primary Peritoneal Cancer | Biological: Bevacizumab|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Sapanisertib | National Cancer Institute (NCI) | Phase 1 | 2014-05-01 | 2017-01-31 |
| NCT02049957 | Breast Cancer | Drug: MLN0128|Drug: Fulvestrant|Drug: Exemestane | Millennium Pharmaceuticals, Inc. | Phase 1|Phase 2 | 2014-02-01 | 2016-02-22 |
| NCT02756364 | Breast Neoplasms | Drug: Fulvestrant|Drug: MLN0128 | Millennium Pharmaceuticals, Inc.|Takeda | Phase 2 | 2016-06-01 | 2016-12-15 |
| NCT02724020 | Clear-cell Metastatic Renal Cell Carcinoma | Drug: Everolimus|Drug: MLN0128|Drug: MLN1117 | Millennium Pharmaceuticals, Inc.|Takeda | Phase 2 | 2016-09-01 | 2016-11-02 |
| NCT02417701 | Recurrent Squamous Cell Lung Carcinoma|Stage IV Squamous Cell Lung Carcinoma | Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Sapanisertib | National Cancer Institute (NCI) | Phase 2 | 2016-10-01 | 2017-01-31 |
| NCT02725268 | Endometrial Neoplasms | Drug: Paclitaxel|Drug: MLN0128|Drug: MLN1117 | Millennium Pharmaceuticals, Inc.|European Network of Translational Research in Ovarian Cancer - EUTROC|European Network of Individualized Treatment in Endometrial Cancer - ENITEC|Takeda | Phase 2 | 2016-06-01 | 2016-11-02 |
| NCT02987959 | Soft-tissue Sarcoma | Drug: TAK-228 | Fox Chase Cancer Center | Phase 2 | 2017-02-21 | 2017-03-02 |
